Khalid Eltawil, MD
Pulmonary Disease · Torrance, CANPI 1396724399
Payments from drug & device makers
Across 223 payments — averaging $116.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$20K
- GSK$1K
- Covidien LP$920
- AstraZeneca$573
- Harmony Biosciences LLC$529
- Inspire Medical Systems, Inc.$479
- plus $3K from 32 others
What the payments were for
- Travel & lodging$3,11612%
- Food & beverage$6,36925%
- Education$16,34563%
- Gifts$1010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 35 | $19,518 |
| GSK | 53 | $1,205 |
| Covidien LP | 15 | $920 |
| AstraZeneca | 19 | $573 |
| Harmony Biosciences LLC | 17 | $529 |
| Inspire Medical Systems, Inc. | 5 | $479 |
| Abiomed | 3 | $305 |
| Boehringer Ingelheim | 7 | $294 |
| Resmed Corp | 3 | $197 |
| Merck | 10 | $162 |
| Jazz Pharmaceuticals Inc. | 6 | $155 |
| Galvanize Therapeutics, Inc | 1 | $135 |
| Haemonetics Corporation | 3 | $133 |
| Electromed, Inc. | 7 | $132 |
| Siemens Medical Solutions USA, Inc. | 1 | $129 |
| Pinnacle Biologics, Inc | 1 | $125 |
| Gilead | 1 | $119 |
| Novartis | 5 | $93 |
| Itamar Medical Inc | 2 | $90 |
| E.r. Squibb & Sons, L.L.C. | 5 | $78 |
| Baxter Healthcare | 1 | $73 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $68 |
| Johnson & Johnson | 3 | $62 |
| ANI Pharmaceuticals, Inc. | 2 | $59 |
| Sanofi | 1 | $28 |
| Circassia Inc. | 2 | $26 |
| Insmed, Inc. | 1 | $26 |
| Boston Scientific | 1 | $25 |
| Irhythm Technologies, Inc. | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Pulmonx Corporation | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Optinose US, Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $18 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Medtronic | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$16,079
- ION$3,000
- Puritan Bennett$435
- Inspire Upper Airway Stimulation System$328
- McGRATH$321
- Impella$266
- AIRSUPRA$227
- ALIYA SYSTEM$135
- Photofrin$125
- OFEV$125
- Vemlidy$119
How this compares
$25,931 in reported general payments places this provider in the 85th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 94 | $108,577 |
| Breo ElliptaFluticasone/Vilanterol | 78 | $51,279 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $21,526 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $18,386 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 26 | $16,229 |
| Advair HfaFluticasone Propion/Salmeterol | 18 | $9,946 |
| Wixela InhubFluticasone Propion/Salmeterol | 40 | $8,371 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 24 | $5,841 |
| Arnuity ElliptaFluticasone Furoate | 16 | $5,507 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $5,057 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 111 | $4,282 |
| Ventolin HfaAlbuterol Sulfate | 24 | $2,019 |
| Armodafinil | 14 | $1,988 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 11 | $964 |
| Trazodone Hcl | 55 | $564 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,205 | $181,592214 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $573 | $26,58233 claims |
| Boehringer IngelheimStiolto Respimat | $294 | $18,38617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Torrance
- William StringerTorrance$1M
- Catherine ObergTorrance$457K
- Toby MaherLos Angeles$27.6M
- David PhamWestminster$5.9M
- Andrew WachtelLos Angeles$5.9M
- Aaron WeinbergIrvine$5.1M
- Michael RothLos Angeles$4.5M
- Namita SoodSacramento$3.7M
- Edward FedermanSan Diego$3.6M
- Sanjay VadgamaSherman Oaks$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.